The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of everolimus (RAD001) with irinotecan (Iri) and cetuximab (C) in second-line metastatic colorectal cancer: Hoosier Oncology Group GI05-102.
Brian Myre
Disclosure not yet available
Menggang Yu
Disclosure not yet available
Joel Picus
Disclosure not yet available
Jose A. Bufill
Disclosure not yet available
Wael A. Harb
Disclosure not yet available
Matthew Burns
Disclosure not yet available
Aaron John Spittler
Disclosure not yet available
Yan Zeng
Disclosure not yet available
Colleen R Currie
Disclosure not yet available
Elena G. Chiorean
Disclosure not yet available